Skip to contentA
Acro Biomedical Co., Ltd.
A
ACBMAcro Biomedical Co., Ltd. Q1 2022 · 10-Q
Revenue$298.50K$298.50K+200.0% vs Q1 2021 Net Income-$3.93M-$3.93MN/M vs Q1 2021 EPS, diluted—
Gross Profit$76,500+159.3% Operating Income-$3,928,588N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Acro Biomedical Co., Ltd. · CIK 1622996 · Engraved from SEC EDGAR
Operating Cash Flow$262,132N/M Margins · derivedGross margin25.6%−4.0 pt vs Q1 2021
Operating margin-1316.1%−1258.8 pt vs Q1 2021
Net margin-1316.2%−1256.4 pt vs Q1 2021
ended Mar 31, 2022 · filed May 16, 2022 · 46 d after period end